Patients with stiff person syndrome are one step closer to having access to a new treatment. Kyverna Therapeutics’ new drug, KYV-101, has been designated by the U.S. Food and Drug Administration ...

These updates will be presented at a company symposium titled, "KYV-101 Anti-CD19 CAR T-Cell Therapy: The Future of Autoimmune Disease Treatment," to be held at 5:45 pm ET on November 18 ...

Furthermore, the safety profile of KYV-101 remains strong ... Ulz is a 3-star analyst with an average return of 2.7% and a 40.66% success rate. Ulz covers the Healthcare sector, focusing on ...

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate. The Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to KYV-101 for ...

The Regenerative Medicine Advanced Therapies designation allows Kyverna to leverage on more expedited meetings and more senior FDA leadership involvement throughout the development cycle for KYV ...

Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H ...